NEONC TECHNOLOGIES HOLDINGS, INC. — Form 8-K
Filed September 28, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 62/100
What the filing says
NeOnc Technologies announced an in-person End-of-Phase 1 Type B meeting with the FDA on November 17, 2026, to discuss NEO212 clinical development, including Phase 2 study design, patient population, endpoints, and potential accelerated approval pathway. The company previously completed Phase 1 dose escalation, selected 610 mg as the recommended Phase 2 dose (after dose-limiting toxicity at 810 mg), and observed notable clinical activity: one glioblastoma patient achieved ~60% tumor reduction with 21 months disease control, and one lung cancer patient with brain metastases achieved ~16 months stable disease.
Why this rating
FDA meeting is meaningful milestone for clinical-stage biotech; Phase 1 completion + positive signals (21-month durability in GBM, 16-month stability in lung cancer brain mets) support advancement. At $67.9M market cap, successful Phase 2 pathway could materially improve valuation trajectory, but meeting provides guidance only—no approval guarantee. Significant but not transformational.
See more from September 28, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.